Product news from the 02/20/07 News Brief

Share this article:
Mylan Pharmaceuticals has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for propranolol hydrochloride extended-release (ER) capsules in 60mg, 80mg, 120mg and 160mg strengths. Propranolol hydrochloride ER capsules are the generic version of Wyeth’s beta blocker, Inderal LA, which had US sales of approximately $201 million for the same strengths for the 12-month period ended Dec. 31, 2006, according to IMS Health. The FDA has granted priority review status to Gilead Science’s hypertension drug ambrisentan on a priority basis. Ambrisentan is a potential treatment for pulmonary arterial hypertension, a type of high blood pressure that affects the lungs and leads to heart failure. Priority FDA review typically takes six months, only half as long as the one year a drug is typically under review.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters